Literature DB >> 21406054

Targeting HIV: past, present and future.

Michèle D Zeier1, Jean B Nachega.   

Abstract

Since the identification of the human immunodeficiency virus (HIV) as the cause of the syndrome of acquired immunodeficiency syndrome (AIDS), there has been an evolution of compounds targeting the replication of the virus in an effort to delay clinical progression. In this review, we revise the mechanism of action of the different groups of drugs. We shortly revisit the older and perhaps lesser used as well as the more recently approved drugs and mention some of the compounds still under investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21406054     DOI: 10.2174/187152611795589690

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  2 in total

1.  Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization.

Authors:  Frauke Christ; Stephen Shaw; Jonas Demeulemeester; Belete A Desimmie; Arnaud Marchand; Scott Butler; Wim Smets; Patrick Chaltin; Mike Westby; Zeger Debyser; Chris Pickford
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 2.  Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.

Authors:  C W Peterson; P Younan; K R Jerome; H-P Kiem
Journal:  Gene Ther       Date:  2013-01-31       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.